OABIW NASDAQ

OmniAb, Inc., established in 2012 and headquartered in Emeryville, California, operates as a biotechnology firm focused on pioneering technologies for the discovery of therapeutic antibodies within the United States. The company's flagship offering is its OmniAb platform, which provides industry collaborators with access to a broad spectrum of antibody repertoires and advanced screening techniques. This capability empowers partners to develop next-generation therapeutic agents. At the heart of the OmniAb platform are proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse. These animals have been genetically engineered to produce antibodies featuring human sequences, thereby streamlining the path to creating human therapeutic candidates. Beyond this core offering, OmniAb also addresses specific industry needs with specialized animal models: OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) facilitate bispecific antibody applications through a shared light chain mechanism. Additionally, OmniTaur provides a solution for challenging targets by leveraging the distinctive structural characteristics of cow antibodies.